Bexmarilimab KOL Event
Faron Pharmaceuticals Oy ("Faron or the Company") Bexmarilimab for Hematological Malignancies KOL Event Press Release, April 19, 2023 TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces plans to host a virtual KOL event via webcast on Tuesday, April 25 at 11.00 EST/16.00 BST/18.00 EEST with Dr. Naval Daver, MD, Associate Professor of Leukemia at The University of Texas MD Anderson Cancer Center; Dr. Mika